Pharming Group (NASDAQ:PHAR) Now Covered by Analysts at Jefferies Financial Group

Equities researchers at Jefferies Financial Group initiated coverage on shares of Pharming Group (NASDAQ:PHAR - Get Free Report) in a research note issued on Monday, Marketbeat.com reports. The firm set a "buy" rating and a $14.00 price target on the stock. Jefferies Financial Group's price objective suggests a potential upside of 69.49% from the company's current price.

Several other research firms have also recently commented on PHAR. HC Wainwright reissued a "buy" rating and issued a $37.00 target price on shares of Pharming Group in a research note on Thursday, October 24th. Oppenheimer cut their target price on shares of Pharming Group from $31.00 to $30.00 and set an "outperform" rating on the stock in a research report on Monday, October 28th.

Pharming Group Price Performance

Shares of PHAR traded up $0.54 during mid-day trading on Monday, hitting $8.26. 8,330 shares of the company traded hands, compared to its average volume of 5,124. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The business has a 50-day moving average of $8.21 and a 200 day moving average of $8.14. Pharming Group has a one year low of $6.65 and a one year high of $13.20. The stock has a market capitalization of $560.28 million, a price-to-earnings ratio of -33.77 and a beta of 0.05.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its position in Pharming Group (NASDAQ:PHAR - Free Report) by 75.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 41,110 shares of the company's stock after purchasing an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.06% of Pharming Group worth $339,000 at the end of the most recent reporting period. 0.03% of the stock is owned by institutional investors and hedge funds.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.